The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) blockbuster anti-PD-1 therapy Keytruda for bladder cancer as part of a combination ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). The FDA said Friday it has approved the drug ...

Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2028.

Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday clearing its PD-L1 inhibitor Imfinzi as part of the first immunotherapy combo ...